Clinical Trials Logo
  1. Home
  2. Hidradenitis Suppurativa
  3. NCT04218422
  4. Details
NCT04218422 Clinical Trial

Battlefield Acupuncture for Pain in Hidradenitis Suppurativa

Hidradenitis Suppurativa Clinical Trial

Official title:
Battlefield Acupuncture to Treat Pain in Hidradenitis Suppurativa

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04218422
Other study ID # IRB-19-12-1642
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 22, 2020
Est. completion date February 20, 2031

Study information
Verified date May 2023
Source Wayne State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will investigate battlefield acupuncture as a treatment for the pain of hidradenitis suppurativa.

Description:

Participants will report their pain level daily for 4 weeks. At week 2 and 3, they will get acupuncture in the ears.

Recruitment information / eligibility
Status Recruiting
Enrollment 32
Est. completion date February 20, 2031
Est. primary completion date December 23, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age 18 years or older - dermatologist-confirmed diagnosis of hidradenitis suppurativa - significant pain from hidradenitis at least twice weekly - stable treatment regimen for hidradenitis during study period Exclusion Criteria: - disease or disfigurement of the ear that prevents battlefield acupuncture of the ears - other chronic pain that will interfere with the ability to rate hidradenitis pain

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Battlefield Acupuncture
Acupuncture at 5 points on the ears
• Sham Acupuncture
Sham acupuncture in 2 points for liver and 1 point for stomach

Locations
Country Name City State
United States WSUPG Dermatology Dearborn Michigan

Sponsors (1)
Lead Sponsor Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Horvath B, Janse IC, Sibbald GR. Pain management in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S47-51. doi: 10.1016/j.jaad.2015.07.046. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Change in Pain Numerical Rating Score Difference in Average Patient self-reported Pain Numerical Rating Score from 0-10, comparing average from 2 weeks prior to treatment with average from 2 weeks after treatment Average Score from scores Recorded daily for 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2